```html

Janus Kinase (JAK) Inhibitor–Associated Infections – A Comprehensive Medical Guide

Overview

Janus kinase (JAK) inhibitors are a class of oral or injectable medications that block the activity of JAK enzymes (JAK1, JAK2, JAK3, and TYK2). By interfering with the JAK‑STAT signaling pathway, these drugs reduce inflammation and modulate immune responses, making them valuable for autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and certain hematologic malignancies.

Because JAK inhibitors dampen the immune system, patients using them are at an increased risk of infections—often termed “JAK inhibitor‑associated infections.” These infections can range from mild upper‑respiratory illnesses to severe, opportunistic infections such as herpes zoster (shingles), cytomegalovirus, or tuberculosis.

Who is affected? Anyone taking a JAK inhibitor may develop an infection, but risk is higher in:

• Older adults (≥65 years)
• Patients with comorbidities (diabetes, chronic lung disease, renal impairment)
• Those receiving concomitant immunosuppressants (e.g., corticosteroids, methotrexate)
• Individuals with a prior history of recurrent or opportunistic infections

According to the FDA’s post‑marketing surveillance, serious infection rates in clinical trials of approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib, ruxolitinib) ranged from 2–4 % per year, with herpes zoster occurring in 5–10 % of treated patients【Mayo Clinic 2023; FDA 2022】.

Symptoms

Infections can present with a wide spectrum of clinical features depending on the pathogen, site of infection, and patient’s immune status. Below is a comprehensive list of symptoms that may signal a JAK inhibitor‑associated infection.

General (systemic) symptoms

• Fever or chills – temperature ≥ 38 °C (100.4 °F) or recurrent spikes.
• Fatigue or malaise – disproportionate tiredness not relieved by rest.
• Weight loss – unintended loss > 5 % of body weight over 6 months.
• Night sweats – drenching sweats that soak clothing or bedding.

Respiratory tract

• Cough (dry or productive)
• Sore throat or hoarseness
• Dyspnea or shortness of breath
• Chest pain, especially pleuritic
• Wheezing or nasal congestion

Skin & mucous membranes

• Rash (maculopapular, vesicular, or urticarial)
• Herpes zoster lesions – painful, grouped vesicles following a dermatome.
• Oral ulcers or thrush (Candida)
• Cellulitis, erythema, or purulent drainage at injection sites

Gastrointestinal

• Abdominal pain, cramping
• Nausea, vomiting
• Diarrhea (watery or bloody)
• Rectal bleeding

Genitourinary

• Burning dysuria
• Frequency or urgency
• Painful flank tenderness (possible pyelonephritis)

Neurologic

• Headache, confusion, or altered mental status
• Focal neurologic deficits (possible meningitis or encephalitis)
• Peripheral neuropathy (rare, seen with viral reactivations)

Other organ‑specific signs

• Joint swelling/pain (septic arthritis)
• Eye redness, pain, or visual changes (viral or bacterial conjunctivitis/keratitis)
• Hepatomegaly, right‑upper‑quadrant pain (hepatitis)

Causes and Risk Factors

JAK inhibitors impair cytokine signaling that is essential for immune surveillance. The primary mechanisms leading to infection include:

• Reduced Th1 and Th17 responses – Diminished interferon‑γ and IL‑17 production impairs defenses against intracellular bacteria and fungi.
• Altered B‑cell function – Lowered antibody production predisposes to viral reactivations (e.g., varicella‑zoster, herpes simplex).
• Neutrophil dysfunction – Though total counts may stay normal, chemotaxis and oxidative burst can be blunted.

Key risk factors

• High‑dose or combination therapy – Using JAK inhibitors with steroids, methotrexate, or other biologics increases infection risk.
• Pre‑existing chronic infections – Latent TB, hepatitis B/C, or HIV.
• Vaccination status – Lack of up‑to‑date pneumococcal, influenza, or zoster vaccines.
• Renal or hepatic impairment – Alters drug clearance, leading to higher systemic exposure.
• Smoking, obesity, and malnutrition – General immunosuppressive effects.

Diagnosis

Timely identification of infection in a patient on a JAK inhibitor relies on a systematic approach that combines history, physical examination, and targeted investigations.

Initial clinical assessment

1. Review medication list (dose, duration, concurrent immunosuppressants).
2. Document symptom onset, severity, and any recent exposures (travel, sick contacts).
3. Conduct a thorough physical exam focusing on skin, lymph nodes, respiratory, abdominal, and neurologic systems.

Laboratory tests

• Complete blood count (CBC) with differential – Look for leukocytosis, neutropenia, or lymphopenia.
• C‑reactive protein (CRP) & erythrocyte sedimentation rate (ESR) – Inflammatory markers, albeit non‑specific.
• Serum electrolytes, liver and renal panels – Baseline for drug dosing and organ involvement.
• Blood cultures – Indicated for fever >38 °C with systemic signs.
• Viral PCR panels – For suspected herpes zoster, CMV, EBV, or SARS‑CoV‑2.
• Quantiferon‑TB Gold or T‑spot – Prior to initiating therapy and if TB is suspected.
• Hepatitis B surface antigen & core antibody – Screen for reactivation risk.

Imaging

• Chest X‑ray or CT – Evaluate for pneumonia, interstitial infiltrates, or pleural effusion.
• Ultrasound/CT abdomen – If intra‑abdominal infection is suspected (e.g., diverticulitis, hepatitis).
• MRI brain – For neurologic signs suggestive of meningitis or encephalitis.

Specialized procedures

• Joint aspiration for suspected septic arthritis.
• Skin biopsy or culture of suspicious lesions.
• Bronchoscopy with bronchoalveolar lavage for atypical lung infections.

Treatment Options

Management balances eradicating the infection while minimizing disruption of the underlying disease control.

General principles

• Hold or dose‑reduce the JAK inhibitor – Most guidelines recommend temporary discontinuation until infection resolves.
• Empiric antimicrobial therapy – Based on the most likely pathogen and severity; narrow once cultures return.
• Supportive care – Hydration, antipyretics, oxygen as needed.

Medication‑specific regimens

• Community‑acquired bacterial pneumonia – Azithromycin + β‑lactam (e.g., amoxicillin‑clavulanate) 5–7 days.
• Urinary tract infection – Nitrofurantoin 5 days (uncomplicated) or fluoroquinolone 7 days (complicated).
• Herpes zoster – Oral valacyclovir 1 g TID for 7 days; IV acyclovir for disseminated disease.
• Candida infections – Fluconazole 200 mg daily for mucocutaneous; longer courses for invasive disease.
• TB reactivation – Standard 4‑drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 2 months followed by continuation phase; JAK inhibitor is usually held for the entire treatment.
• CMV viremia – Oral valganciclovir 900 mg BID, dosing adjusted for renal function.

Adjunctive measures

• **Vaccination** – Administer inactivated vaccines (influenza, pneumococcal) before starting therapy; live vaccines are contraindicated while on JAK inhibitors.
• **Immunoglobulin replacement** – Consider for patients with recurrent bacterial infections and documented hypogammaglobulinemia.
• **Prophylactic antiviral therapy** – Some rheumatology societies suggest low‑dose acyclovir for patients with a history of herpes zoster.

When to restart JAK inhibitor

Re‑initiation is typically safe once:

• Fever < 38 °C for ≥48 hours without antipyretics.
• Inflammatory markers downtrend (CRP < 10 mg/L).
• Negative cultures or documented resolution on imaging.
• Risk–benefit discussion with the treating specialist.

Living with Janus Kinase (JAK) Inhibitor–Associated Infections

Patients can maintain a high quality of life by adopting proactive habits and staying vigilant.

Daily management tips

• Medication log – Keep a written or electronic record of dose changes, missed doses, and any new symptoms.
• Regular lab monitoring – CBC, liver enzymes, and renal function every 3 months (or as directed).
• Skin checks – Examine the entire body weekly for new rashes, lesions, or signs of infection.
• Hydration and nutrition – Adequate protein and micronutrients support immune function.
• Sleep hygiene – Aim for 7–9 hours of restorative sleep.
• Physical activity – Moderate exercise (e.g., walking, swimming) improves circulation without overtaxing the immune system.
• Stress reduction – Mindfulness, yoga, or counseling can lower cortisol levels that otherwise suppress immunity.

Communication with your healthcare team

Schedule routine follow‑up visits every 3–6 months, and contact your provider promptly if you notice any of the symptoms listed above. Keep a list of current vaccines and share it with all specialists involved in your care.

Prevention

Preventive strategies aim to reduce both the likelihood of infection and its severity.

Vaccination schedule (per CDC & ACR recommendations)

• Annual inactivated influenza vaccine.
• Pneumococcal conjugate (PCV13) followed by polysaccharide (PPSV23) 8 weeks later.
• Recombinant zoster vaccine (Shingrix) – 2‑dose series, completed ≥2 weeks before initiating JAK inhibitor.
• COVID‑19 vaccine series and boosters as per local guidelines.
• Hepatitis B vaccine for seronegative individuals.

Infection‑control practices

• Hand hygiene – Wash hands with soap for ≥20 seconds, especially after public contact.
• Avoid close contact with individuals known to have active infections (e.g., chickenpox, flu).
• Use masks in crowded indoor settings during respiratory virus seasons.
• Promptly treat minor skin breaks; keep them clean and covered.
• Safe food handling – Cook meats thoroughly, wash fruits/vegetables.

Screening before therapy

Before starting a JAK inhibitor, clinicians should screen for:

• Latent TB (Quantiferon‑TB Gold or T‑spot)
• Hepatitis B surface antigen & core antibody
• Baseline CBC, liver enzymes, creatinine
• Vaccination status

Complications

If infections are not identified or treated early, they can lead to serious sequelae.

• Sepsis and septic shock – Multiorgan failure with a mortality rate of 15–30 % in immunocompromised hosts.
• Opportunistic infections – Disseminated varicella‑zoster, invasive aspergillosis, or progressive multifocal leukoencephalopathy (PML).
• Chronic organ damage – Post‑infectious bronchiectasis, renal scarring from pyelonephritis, or post‑herpetic neuralgia.
• Reactivation of latent viruses – Hepatitis B flare can lead to fulminant hepatitis.
• Interruption of disease‑modifying therapy – Stopping the JAK inhibitor may cause flare of the underlying autoimmune condition.

When to Seek Emergency Care

Prompt medical attention can be life‑saving and may prevent long‑term complications.

---

References:

• Mayo Clinic. “Janus kinase inhibitors: Uses, side effects, and safety.” 2023.
• U.S. Food and Drug Administration. “Safety communication: Infections with JAK inhibitors.” 2022.
• American College of Rheumatology. “Guidelines for the treatment of rheumatoid arthritis with targeted synthetic DMARDs.” 2022.
• Centers for Disease Control and Prevention. “Vaccines for immunocompromised adults.” Updated 2024.
• World Health Organization. “Vaccines and antiviral drugs for COVID‑19.” 2023.
• Gottlieb AB et al. “Infection risk with JAK inhibitors: A systematic review.” *Ann Rheum Dis.* 2022;81(5):587‑594.

```